Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $360,000.00 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $900.00, for a total transaction of $360,000.00. Following the completion of the sale, the director directly owned 603 shares in the company, valued at approximately $542,700. The trade was a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathryn Guarini also recently made the following trade(s):

• On Wednesday, September 2nd, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $850.00, for a total value of $340,000.00.
• On Monday, August 10th, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $800.00, for a total value of $320,000.00.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $902.90 on Friday. The stock has a market cap of $92.96 billion, a PE ratio of 19.49, a price-to-earnings-growth ratio of 1.38 and a beta of 0.10. The business has a 50-day simple moving average of $802.45 and a 200-day simple moving average of $741.95. The company has a quick ratio of 3.66, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $991.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company’s revenue was up 36.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $11.83 earnings per share. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 51.86 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.30%.

Analyst Ratings Changes

REGN has been the topic of several recent research reports. Bank of America upped their price objective on Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Monday. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $960.00 to $980.00 and gave the company a “buy” rating in a report on Wednesday, October 21st. Royal Bank Of Canada lifted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the company a “sector perform” rating in a report on Monday. Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the company an “equal weight” rating in a research note on Monday. Finally, Truist Financial increased their price target on shares of Regeneron Pharmaceuticals from $780.00 to $982.00 and gave the stock a “buy” rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $898.97.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron is advancing ALN-CIDEB into a Phase 3 study for liver disease, a step forward for its development pipeline. ALN-CIDEB Phase 3 study
• Positive Sentiment: Recent coverage cited solid earnings-estimate revisions as a possible support for further gains. The company’s latest reported quarter also beat analyst expectations for earnings and revenue, reinforcing its recent fundamental momentum. Earnings estimate revisions
• Neutral Sentiment: Regeneron joined the Mary Tyler Moore Vision Initiative consortium as a founding member. The collaboration connects the company with a vision-research effort, but no near-term financial impact was disclosed. Vision initiative consortium announcement
• Negative Sentiment: Multiple insider sales may be weighing on sentiment after the stock’s recent run-up. Director Huda Zoghbi sold 7,439 shares, reducing her holding by about 81%; EVP Joseph Larosa sold 4,466 shares, while director Christine Poon sold 7,830 shares. Such sales are not necessarily signals about company prospects, but the cluster may add to near-term caution. Zoghbi SEC filing Larosa SEC filing Poon SEC filing

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $26,000. Armstrong Advisory Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 466.7% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 28 shares during the last quarter. Activest Wealth Management increased its holdings in shares of Regeneron Pharmaceuticals by 780.0% during the 3rd quarter. Activest Wealth Management now owns 44 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 39 shares during the last quarter. Alpine Bank Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $34,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.